Active Immunotherapy Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

How It Works

1. Share a Few Details — Enter your cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Immunotherapy Clinical Trials FAQ

What types of immunotherapy are being tested in clinical trials?

Active immunotherapy trials are testing checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4), CAR-T cell therapies, bispecific T-cell engagers, cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and combinations of these approaches. Each type works differently to help the immune system identify and destroy cancer cells.

Who is a good candidate for an immunotherapy clinical trial?

Candidacy depends on your cancer type, biomarker status (like PD-L1 expression or MSI-H/dMMR status), prior treatments, and overall health. Some immunotherapy trials prefer patients who have not received prior immunotherapy; others specifically target patients who progressed on PD-1 inhibitors. Your oncologist can review your tumor biomarker profile to identify the best options.

What are common side effects of immunotherapy in clinical trials?

Immunotherapy can cause immune-related adverse events (irAEs) — the immune system may attack healthy tissues as well as cancer. Common irAEs include fatigue, rash, colitis (diarrhea), pneumonitis (lung inflammation), thyroid problems, and liver inflammation. Most are manageable with steroids if caught early. Clinical trial staff monitor participants closely and have protocols for managing these effects.

Do I need to stop other cancer treatments before joining an immunotherapy trial?

It depends on the specific trial. Some immunotherapy trials test a new agent on top of standard chemotherapy or targeted therapy. Others require a washout period after prior therapy. The trial protocol defines exactly what is permitted — Trialify's eligibility questionnaire highlights these requirements so you can discuss them with your oncologist before applying.

Immunotherapy Trials by Cancer Type

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.